ProKidney Business Combination SPAC — Q1 2022 Form 10-Q
Entity and period: This filing is by Social Capital Suvretta Holdings Corp. III, a Cayman Islands blank-check company, for the quarter ended March 31, 2022. It is not an operating-company 10-Q filed by ProKidney Corp. The SPAC had not commenced operations; its activities centered on seeking a business combination and the proposed transaction with ProKidney LP.
Financial results and position
| Metric | Q1 2022 / March 31, 2022 | Comparison / prior period |
|---|---|---|
| Operating revenue | None | The SPAC expects no operating revenue before a business combination, at the earliest. |
| Operating and formation costs | $4.006 million | $5,182 from inception through March 31, 2021; the periods are not directly comparable. |
| Net loss | $3.981 million; $0.12 per Class A and Class B share | $5,182 from inception through March 31, 2021. |
| Cash from operations | $(388,599) | $(138) from inception through March 31, 2021. |
| Cash outside Trust Account | $51,889 | $440,488 at December 31, 2021. |
| Trust Account marketable securities | $250.034 million | $250.008 million at December 31, 2021. |
| Current liabilities / working capital | $5.413 million current liabilities; $4.818 million working capital deficit | Current liabilities were $1.880 million at December 31, 2021. |
| Debt | No long-term debt reported at quarter-end; $7.7 million deferred underwriting fee payable, due only if a business combination closes | On April 20, the Sponsor provided a non-interest-bearing note facility of up to $1.5 million; $250,000 was drawn April 26. |
Accrued expenses rose to $5.342 million from $1.865 million, including transaction-related legal, consulting, and other expenses. The filing reports no operating margins because the SPAC has no operating revenue.
Material developments and proposed transaction
- On January 18, 2022, the SPAC agreed to combine with ProKidney LP, subject to closing conditions. The proposed transaction uses an Up-C structure; substantially all operating assets and business would be held indirectly through ProKidney.
- PIPE investors subscribed for 57.5 million shares at $10 each, for a stated aggregate commitment of $575 million. This includes $156.4 million committed by Sponsor-related investors; certain ProKidney-related investors committed at least $50 million, with an option to increase that amount to $100 million or elect units instead.
- The agreement provides for 17.5 million earnout restricted common units and 17.5 million earnout restricted stock rights, vesting in three equal tranches at share-price thresholds of $15, $20, and $25, or on specified change-of-control events.
- At March 31, the Trust Account held approximately $250 million, and 25 million Class A public shares were subject to possible redemption. The filing does not report a completed transaction or final redemption outcome.
- Transaction expenses contributed materially to the quarter’s loss: management attributed $3.282 million of operating and formation costs to the proposed combination.
Outlook, risks, and unusual items
- Going concern: Management said the low operating cash balance, working-capital deficit, dependence on possible additional financing, and risk of mandatory liquidation raise substantial doubt about the SPAC’s ability to continue as a going concern for one year from issuance of the statements. The SPAC had until July 2, 2023, subject to any permitted extension, to complete a business combination; failure to do so would trigger liquidation provisions.
- Funding uncertainty: Sponsor and affiliate loans may be available but are generally not obligated. The April Sponsor note is capped at $1.5 million, and its balance is payable upon the earlier of July 2, 2023 or the business-combination effective date.
- Controls: Management concluded disclosure controls were not effective because of a material weakness in accounting for complex financial instruments. Remediation steps included expanded review procedures; management said the financial statements were fairly presented.
- Legal and regulatory: Purported shareholders sent demand letters alleging disclosure deficiencies relating to the ProKidney transaction; the Company said it believes the allegations are meritless. The SEC’s proposed March 2022 SPAC rules could increase disclosure, compliance, timing, and liability burdens if adopted.
- Other risks: Management noted that COVID-19 could adversely affect the company or its search for a target, but the impact was not determinable. Sponsor indemnification of certain Trust Account claims may be of limited value because the SPAC had not verified the Sponsor’s ability to pay.
- No numerical earnings or revenue guidance was provided. The filing states that the transaction remains subject to conditions and does not assure successful completion.
Most important facts for investors to verify
- Whether the ProKidney business combination closed, and the final terms, timing, redemptions, and cash delivered at closing.
- Whether the $575 million PIPE commitment was funded in full, including any investor elections to buy ProKidney units instead of SPAC shares.
- Post-transaction ownership, dilution, earnout mechanics, and the effects of Class B share conversion and redemption levels.
- Use of the Sponsor note facility and whether additional financing was required to fund transaction costs and operations.
- Progress in remediating the material weakness and any resolution or escalation of the shareholder demand letters.